Financial Reports: Merck 1Q Revenues: $11.6 billion (+1%) 1Q Earnings: $1.0 billion (+248%) Comments: The company took $1.8 billion in one-time charges in 1Q11, including a $500 million payment to Johnson & Johnson to settle Remicade/Simponi arbitration and $302 million in in-process R&D writeoffs; it had $2.3 billion in one-time charges in 1Q10. Pharma revenues grew 2% to $9.8 billion, led by Singulair (+14% to $1.3 billion), Remicade (+12% to $753 million) and Januvia (+45% to...